Retatrutide, by Soma Corp., is gaining considerable attention as a innovative therapy for metabolic control . This unique compound merges the mechanism of a GLP-1 receptor activator and a GIP receptor agonist , intended to simply promote metabolic improvements but also improve associated metabolic factors. Initial clinical studies have demonstrated